November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests statins are ...
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional ...
November 3, 2017 — VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C round ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System. The RXi Mini System debuted at the 29th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver.
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the ...
November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion ...
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver. The results provide fresh insights into the optimal treatment of patients with acute coronary syndrome (ACS) using the COMBO Dual Therapy Stent.
The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium, Oct. 29-Nov. 2 in Denver.
James A. Brink, M.D., FACR, chair of the American College of Radiology (ACR) Board of Chancellors, met with the House Committee on Science, Space and Technology Subcommittee on Energy to urge more research on low-dose medical radiation effects to inform future safety practices. He also told the Committee that medical imaging and radiation oncology save lives.
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy ...
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the ...
Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery. Results of the economic analysis, which is the first-of-its-kind report on intermediate-risk patients, were presented as a late-breaking clinical trial at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.